Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some core safety/dosing concepts align (IV administration and ACS context consistent with NSTE-ACS), but multiple claims cannot be verified from the provided label excerpts (trade name/market usage) and the 'acute coronary settings/PCI' wording is broader than the label’s specific indication for NSTE-ACS without directly citing PCI.
Category Scores
Accurate Statements
Tirofiban is typically supplied as an intravenous medication.
Supported by Section 2.1/2.2 excerpt: AGGRASTAT recommended dosage is administered intravenously and Section 2.2 states 'For intravenous use only.'
Tirofiban is used in acute coronary settings.
Partially supported: Label Section 1 indicates use in non-ST elevation acute coronary syndrome (NSTE-ACS), which is an acute coronary condition.
Unsupported Statements
Tirofiban is commonly marketed under the trade name Aggrastat.
Provided label excerpts do not address marketing/trade-name prevalence; label text only shows product name AGGRASTAT® but does not support 'commonly marketed under' wording.
The widely cited brand name for tirofiban in major markets is Aggrastat.
Provided label excerpts do not support claims about 'widely cited' brand naming across markets.
Tirofiban is used, for example, in certain patients undergoing PCI.
The provided label excerpts supplied for indication (Section 1) specify NSTE-ACS but do not explicitly mention PCI; without an explicit PCI statement in the provided excerpts, this is not supported.
Contradictions
Important Omissions
The label indication is specifically for 'non-ST elevation acute coronary syndrome (NSTE-ACS)' and includes a combined endpoint definition (death, myocardial infarction, or refractory ischemia/repeat cardiac procedure). The AI response does not reflect the NSTE-ACS specificity or endpoint.
Importance:
Moderate
No dosing/administration regimen details are provided (e.g., 25 mcg/kg IV bolus within 5 minutes followed by 0.15 mcg/kg/min up to 18 hours, and renal dose adjustment).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes no dosing regimen and uses broader indications ('acute coronary settings', 'for example... undergoing PCI') that are not explicitly supported by the provided excerpts; this could lead to overbroad application if used for clinical decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported claims about market/trade-name prominence and PCI are included; indication wording is broader than the specific NSTE-ACS label language provided.
Suggested Improvement
Limit indication statements to 'non-ST elevation acute coronary syndrome (NSTE-ACS)' per Section 1; avoid claims about PCI unless the provided labeling excerpts explicitly mention it; remove or qualify trade-name/market-prevalence assertions not present in the label excerpts.